Trials / Unknown
UnknownNCT05106049
Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.
Early Detection of Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease by Measuring Serum Adiponectin Level.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 90 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Early detection of renal impairment in patients with non-alcoholic fatty liver disease and its correlation with serum Adiponectin level.
Detailed description
Detection of serum Adiponectin by ELISA technique using (EIA-3418) KIT, DRG international inc., USA
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | serum Adiponectin | serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions. |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2022-12-01
- Completion
- 2023-01-01
- First posted
- 2021-11-03
- Last updated
- 2021-11-03
Source: ClinicalTrials.gov record NCT05106049. Inclusion in this directory is not an endorsement.